PubMed HealthSearch

PubMed · 9644847

[Bioartificial liver].

Abstract

Fulminant hepatic failure remains without satisfactory medical treatment and with a mortality rate of nearly 90%. Liver transplantation is the only chance to save these patients. However, there is a shortage of donors and many patients die before transplantation. It is thus necessary to develop a liver support system to help maintain patients alive, neurologically intact until an organ becomes available for transplantation, or ideally until hepatic regeneration. Early systems had only a depuration function, but now these systems include hepatocytes to replace most hepatic functions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Reis. 1998. [Bioartificial liver].. https://pubmed.ncbi.nlm.nih.gov/9644847/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Government-owned inventions; availability for licensing. National Institutes of Health, Public Health Service, DHHS. Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Cell Transplantation

Current and future modalities for functional renal replacement.

Approximately 310,000 Americans suffer from end-stage renal disease, with more than 70,000 new cases reported each year. Advances in immunosuppressive therapy for transplanted patients, in addition to the refined care of patients who are dependent on dialysis, have led to an improved survival for patients with renal failure. Structural, molecular, and pharmacologic developments continue to enhance the efficacy and safety of dialysis in the future. In addition, progressive improvements in the past 2 decades in organ transplantation, a greater insight into the immunobiology of graft rejection, and better surgical and medical management have resulted in improved outcomes. Although renal xenotransplantation is still in its early stages of development, additional research is leading this technology forward. Recent successes in harvesting and expanding renal cells in vitro and the development of biologically active synthetic materials allow for the creation of three-dimensional functioning renal units, which, in the future, may be applied ex vivo or in vivo for partial or full replacement of kidney function.

Cell Transplantation